Promising Phase II Results for Cadonilimab in Neoadjuvant Therapy at ESMO Asia 2025 Cadonilimab shows significant promise as a neoadjuvant therapy in resectable gastric cancer, with impressive response rates presented at ESMO Asia 2025.

Promising Phase II Results for Cadonilimab in Neoadjuvant Therapy at ESMO Asia 2025 #Hong_Kong #ESMO_Asia #Akeso #Cadonilimab

Innovent Biologics to Showcase Promising Oncology Molecules at ESMO Asia 2024 Innovent Biologics will present key clinical data on several innovative oncology treatments at ESMO Asia 2024, highlighting its advancements in cancer therapies.

Innovent Biologics to Showcase Promising Oncology Molecules at ESMO Asia 2024 #China #Suzhou #Innovent_Biologics #oncology #ESMO_Asia